ACRV
ACRIVON THERAPEUTICS INC

1,175
Mkt Cap
$64.32M
Volume
451,304.00
52W High
$5.65
52W Low
$1.05
PE Ratio
-0.82
ACRV Fundamentals
Price
$1.66
Prev Close
$1.70
Open
$1.69
50D MA
$1.71
Beta
1.57
Avg. Volume
884,471.71
EPS (Annual)
-$2.02
P/B
0.47
Rev/Employee
$0.00
$23.07
Loading...
Loading...
News
all
press releases
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Recommendation of "Moderate Buy" from Analysts
Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven analysts that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold ratin...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Acrivon Therapeutics (NASDAQ:ACRV) Releases Earnings Results, Meets Estimates
Acrivon Therapeutics (NASDAQ:ACRV - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.49) earnings per share (EPS) for the quarter, meeting the consensus...
MarketBeat·2d ago
News Placeholder
Acrivon Therapeutics (ACRV) Projected to Post Earnings on Thursday
Acrivon Therapeutics (NASDAQ:ACRV) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 26. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-26-acrivon-therapeutics-inc-stock...
MarketBeat·4d ago
News Placeholder
Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's Why
Acrivon Therapeutics, Inc. (ACRV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·19d ago
News Placeholder
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer
Acrivon Therapeutics (NASDAQ:ACRV) hosted a webcast featuring a key opinion leader (KOL) panel focused on the company's ongoing ACR-368 registrational-intent Phase 2B study in endometrial cancer...
MarketBeat·23d ago
News Placeholder
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Sees Large Drop in Short Interest
Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) was the recipient of a significant drop in short interest in January. As of January 30th, there was short interest totaling 2,024,627...
MarketBeat·1mo ago
News Placeholder
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Sees Large Increase in Short Interest
Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) was the target of a large growth in short interest in January. As of January 15th, there was short interest totaling 7,521,144 shares, a...
MarketBeat·2mo ago
News Placeholder
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Average Rating of "Moderate Buy" by Brokerages
Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) have received a consensus rating of "Moderate Buy" from the seven analysts that are presently covering the company, MarketBeat.com...
MarketBeat·2mo ago
News Placeholder
Adam Levy Acquires 8,832 Shares of Acrivon Therapeutics (NASDAQ:ACRV) Stock
Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) CFO Adam Levy bought 8,832 shares of the company's stock in a transaction on Wednesday, January 14th. The shares were acquired at an average...
MarketBeat·2mo ago
News Placeholder
Acrivon Therapeutics (NASDAQ:ACRV) CFO Adam Levy Acquires 8,832 Shares
Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) CFO Adam Levy bought 8,832 shares of the firm's stock in a transaction on Wednesday, January 14th. The stock was bought at an average price...
MarketBeat·2mo ago
<
1
2
...
>

Latest ACRV News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.